Clinical bottom line
Early administration of intravenous fibrinolytics in the emergency department (ED) for patients with massive pulmonary embolism (PE) can be life-saving by rapidly restoring pulmonary perfusion and improving hemodynamics. Evidence supports fibrinolytic therapy in patients presenting with hemodynamic instability or right ventricular dysfunction confirmed by bedside echocardiography. However, bleeding risks, especially intracranial hemorrhage, necessitate careful patient selection and risk-benefit assessment. Adjunctive or alternative reperfusion strategies, including catheter-directed therapies and extracorporeal membrane oxygenation (ECMO), may be considered in select cases. Prompt diagnosis and multidisciplinary management in the ED are critical to optimizing outcomes (Draxler et al., 2021; Hailu et al., 2021).
What the evidence shows
Massive PE, defined by sustained hypotension or shock, carries high mortality without rapid reperfusion. Draxler et al. (2021) review interventional reperfusion strategies, emphasizing that systemic fibrinolysis remains the first-line treatment in unstable patients due to its rapid action.
Bedside focused echocardiography in the ED is a valuable tool for early detection of right ventricular strain and guides fibrinolytic decision-making (Borloz et al., 2011; Wu et al., 2018). Early identification facilitates timely initiation of fibrinolytics.
Hailu et al. (2021) report successful fibrinolytic use in a patient with massive PE despite a history of subdural hemorrhage, highlighting the complexity of balancing bleeding risks with life-saving therapy.
Adjunctive therapies such as catheter-directed thrombolysis and ECMO can be considered when systemic fibrinolysis is contraindicated or ineffective (Russ et al., 2017; Wang et al., 2018).
Sundin et al. (2025) underscore the importance of optimizing early diagnosis and management pathways in the ED to reduce delays and improve survival.
Caveats and uncertainty
Fibrinolytic therapy carries significant bleeding risk, including intracranial hemorrhage, necessitating individualized risk assessment.
Data on fibrinolytic use in patients with relative contraindications remain limited and largely anecdotal.
Optimal dosing regimens and timing in the ED setting require further standardization.
Comparative effectiveness of systemic versus catheter-directed fibrinolysis in the acute ED context is not fully established.
The role of ECMO and surgical embolectomy is evolving but limited by resource availability and expertise.
How this may change practice
Emergency clinicians should maintain a high index of suspicion for massive PE in unstable patients and utilize bedside echocardiography promptly.
Early initiation of intravenous fibrinolytics should be considered in eligible patients with confirmed or highly suspected massive PE.
Multidisciplinary collaboration with cardiology, pulmonology, and critical care can facilitate advanced reperfusion strategies when fibrinolysis is contraindicated or insufficient.
Protocols incorporating rapid diagnostic algorithms and risk stratification tools may improve timely treatment.
Ongoing education on balancing bleeding risks and benefits is essential for informed clinical decision-making.